Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors
Source : https://www.cjhp-online.ca/index.php/cjhp/article/view/3066
Michael Fralick Sinai Health System, University of Toronto Diana Martins Unity Health Toronto Mina Tadrous Women's College Research Institute, Women's College Hospital; ICES; University of Toronto Tara Gomes Unity Health...
Conclusions: The cardiovascular outcome trials appeared to have an important impact on the dispensing of SGLT2 inhibitors in Canada.
Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35391843/
doi: 10.3389/fcvm.2022.854230. 1 Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 2 Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital,...
Conclusion: SGLT2 inhibition lowers daytime and nighttime ambulatory systolic and diastolic BP in normotensive non-diabetic subjects. Twenty-four jour changes are pronounced and comparable to those described in diabetic or hypertensive subjects. Baseline ambulatory BP was the only identified determinant of systolic and diastolic BP response....
Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35397165/
doi: 10.1210/clinem/dgac210. Online ahead of print. 1 Department of Endocrinology, Henan Provincial Key Medicine Laboratory of Intestinal Microecology and Diabetes, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou,...
Conclusions: Empagliflozin may be a superior initial therapy for patients with T2DM at risk of CVDs; its cardiovascular benefits may be associated with shifts in gut microbiota and plasma metabolites.
SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35329796/
The incidence of both diabetes mellitus type 2 and heart failure is rapidly growing, and the diseases often coexist. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new antidiabetic drug class...
Conclusions: The expected paradigm shift in treatment strategies was reflected in the most recent 2021 guidelines published by the European Society of Cardiology, recommending dapagliflozin and empagliflozin as first-line treatment for heart failure patients with reduced ejection fraction. Moreover, the recent results of the EMPEROR-Preserved...
Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy-effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker - BMC Nephrology
Source : https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-02747-1
Background Host factors such as angiotensin-converting enzyme 2 (ACE2) and the transmembrane protease, serine-subtype-2 (TMPRSS2) are important factors for SARS-CoV-2 infection. Clinical and pre-clinical studies demonstrated that RAAS-blocking agents can...
Conclusions: Our study indicated that there is no upregulation regarding host factors potentially promoting SARS-CoV-2 virus entry into host cells when the SGLT2-blocker empagliflozin, telmisartan and the DPP4-inhibitor blocker linagliptin are used. The results obtained in a preclinical, experimental non-diabetic kidney failure model need...